Clover Health (CLOV)
Offers wide-network Medicare Advantage plans powered by point-of-care physician software.
Something off on this page? Send us feedback.
Offers wide-network PPO and HMO Medicare Advantage plans, earning premiums while using Clover Assistant to bring patient data and care recommendations into physicians' workflows. Counterpart Health licenses the platform to external payors and providers, but insurance remains the sole reportable segment and depends on CMS-regulated Medicare economics.
Offers PPO and HMO Medicare Advantage plans across several U.S. states, with wide-network PPO coverage as the flagship product. Premiums generate nearly all revenue, while Clover Assistant brings claims, clinical, medication, and other patient data into physicians' workflows to support earlier identification and management of chronic disease.
Extends the platform outside its own health plans through Counterpart Health, which licenses Counterpart Assistant to other payors and providers. Clover Home Care complements the plan network with longitudinal, home-based primary care for members with complex needs.
Pairs broad physician choice with point-of-care data and a feedback loop between plan and provider information. Insurance remains the sole reportable segment, Counterpart is not yet material to overall operations, and results depend on CMS Medicare Advantage payments, quality ratings, benefit rules, and physician adoption.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | Deutsche Bank | Initiate | Rating: —Target: — | Target: $6 |
| Aug 6, 2026 | UBS | Reiterate | Rating: —Target: $4.75 | Target: $5 |
| Jul 21, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $4.20 | Target: $5.50 |
| Jun 11, 2026 | UBS | Reiterate | Rating: —Target: — | Target: $4.75 |
| Jun 4, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $2.50 | Target: $4.20 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $201.3M · Total debt $0 · Total assets $720.3M · Shareholders' equity $376.3M
- Revenue
- $743.2M
- Operating income
- $28.0M
- Net income
- $28.0M
No dividends on record.
| Institutions | ≈ 28.57% | 150.48M shares | |
|---|---|---|---|
| 242 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 6.27% | 33.04M shares | |
| 13 holders · as of Sep 17, 2026 | |||
| Other | ≈ 65.16% | 343.16M shares | |
| remainder | |||
526.68M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 6.67% | 35.11M A | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.42% | 18.04M A | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 2.06% | 10.85M A | as of Jun 30, 2026 |
Vivek GaripalliInsiderdirector, 10 percent owner | 1.98% | 8.59M B · 1.86M A | filed Jan 9, 2026 |
State Street CorpInstitution | 1.93% | 10.18M A | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 17, 2026 | Jamie L. Reynoso | officer: CEO, Medicare Advantage | −1,921 | $4.56 |
| Sep 16, 2026 | Joseph Frank Oldakowski | officer: VP OF FINANCE AND CONTROLLER | −3,170 | $4.64 |
| Sep 15, 2026 | Conrad Wai | officer: CEO, Counterpart Health | −300,000 | $4.72 |
| Sep 15, 2026 | Karen Soares | officer: Chief Legal Officer | −6,846 | $4.78 |
| Sep 15, 2026 | Jamie L. Reynoso | officer: CEO, Medicare Advantage | −9,273 | $4.78 |
- Humana
Heavyweight Medicare Advantage rival for senior plan members
- UnitedHealth Group
Largest MA brand rival with broad PPO, HMO and SNP coverage
- CVS Health
Aetna MA plans contest PPO/HMO members with CVS assets
- Elevance Health
Large MA and Carelon platform competitor
- Alignment Healthcare
Focused MA peer using senior-care technology and AVA
- Centene
Wellcare overlaps in government-sponsored MA and SNP plans
- Agilon Health
Physician enablement rival for MA value-based care
- Evolent
Payer/provider tech rival in value-based clinical enablement
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Clover Health | $4.59 | +1.20% | $2.35B | — | 74.0 | 1.0 | +55.6% |
| Humana | $372.92 | −1.50% | $45.39B | 35.9 | 30.2 | 0.3 | +26.2% |
| UnitedHealth Group | $373.53 | −1.07% | $342.88B | 24.3 | 17.5 | 0.8 | +0.4% |
| CVS Health | $87.49 | −0.13% | $111.77B | 23.2 | 10.8 | 0.3 | +7.3% |
| Elevance Health | $403.45 | −1.43% | $88.77B | 18.2 | 14.8 | 0.4 | +0.8% |
| Alignment Healthcare | $7.90 | −5.16% | $1.73B | 44.6 | 28.5 | 0.4 | +31.6% |
| Centene | $63.71 | −1.97% | $32.10B | — | 14.1 | 0.2 | +9.9% |
| Agilon Health | $88.28 | +0.28% | $1.47B | — | — | 0.2 | +7.2% |
| Evolent | $3.69 | −0.14% | $415.1M | — | 11.0 | 0.2 | +46.9% |
| Median | 24.3 | 14.8 | 0.3 | +8.6% |